Myriad Genetics (MYGN) Retained Earnings (2010 - 2026)

Myriad Genetics has disclosed Retained Earnings across 17 years of filings, most recently posting -$1.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 192700.0% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 192700.0% YoY), while the FY2025 annual figure was -$1.1 billion, down 140237.5% from the prior year.
• Retained Earnings fell to -$1.2 billion in Q1 2026, from -$1.1 billion in the prior quarter.
• Over the last five years, Retained Earnings for MYGN reached as high as -$100000.0 in Q3 2024 and fell as low as -$1.2 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$8.9 million (2022), against an average of -$344.4 million.
• Annual changes were most pronounced in 2024 — Retained Earnings soared 99.98% — and 2026, when it plunged 192700.0%.
• A 5-year view of Retained Earnings shows it stood at -$366.2 million in 2022, then slumped by 71.9% to -$629.5 million in 2023, then jumped by 99.87% to -$800000.0 in 2024, then sank by 140237.5% to -$1.1 billion in 2025, then retreated by 3.04% to -$1.2 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$1.2 billion, -$1.1 billion, and -$100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.